A new way to
guide patient care

Testing and interpretation supported
by clinical research

Our testing is validated and developed through the use of in-house clinical studies. We also reference publications and research in each of our reports to provide clinical evidence to our interpretations.


  • Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
    Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but variability in manual plate-based assays has limited their use. We examined the relationship between CSF biomarkers, as measured by a novel automated immunoassay platform, and amyloid positron emission tomography.
  • NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
    In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines.